ASSESSMENT OF IMPACT OF GENE POLYMORPHISM IL-10 ON OUTCOMES OF CHRONIC VIRAL HEPATITIS IN KAZAKH POPULATION: CASE-CONTROL STUDY
Purpose of the study is analysis of the polymorphism of cytokine gene IL10 (rs1800872) in patients of Kazakh population with chronic viral hepatitis to assess the risk of liver cirrhosis.
Materials and methods. In total, 652 people were studied. There were 90 patients with liver cirrhosis of viral etiology (LC), 296 people with chronic viral hepatitis (CVH) B and / or C and 266 donors of control group (absence of liver disease in anamnesis, HBV and HCV-negative). Polymorphism of IL10 (rs1800872) were genotyped by Real-time PCR.
Results. The frequency of allele A is significantly higher in patients with liver cirrhosis (OR = 1,56, 95% CI 1,11 – 2,19, p=0,01) and chronic viral hepatitis (OR = 1,44, 95% CI 1,14 -1,82, p=0,002) in comparison with control group. The incidence of genotype AA and AC is also significantly higher in patients with liver cirrhosis (OR = 2,38, 95% CI 1,27 – 4,45, p=0,006) and chronic viral hepatitis (OR = 2,10, 95% CI 1,41 -3,13, p <0,001) compared with control. Thus, the allele A and genotype AA and AC are associated with the development of chronic viral liver diseases in Kazakh population.
Conclusion. The study shows that IL-10 gene polymorphism rs1800872 plays an important role in the risk of developing of liver cirrhosis and chronic viral hepatitis in Kazakh population.
M. R. Massabayeva1, N. E. Aukenov1, D. B. Babenko2, I. S. Azizov2,
S. B. Maukayeva1, A. Z. Tokayeva1, M. O. Khamitova1
1 Semey State Medical University, Semey, Kazakhstan;
2 Karaganda State Medical University, Karaganda, Kazakhstan.
1. Арсентьева Н. А., Семенов А. В., Тотолян А. А. Роль полиморфизма генов цитокинов при вирусном гепатите С // Инфекция и иммунитет. 2012. Т. 2. №. 4. С. 687-698.
2. Бодиенкова Г. М., Титова Ж. В. Роль полиморфизма и экспрессии отдельных генов цитокинов в формировании патологии (Обзор) // Успехи современного естествознания. 2015. №. 1. C. 4.
3. Гржибовский А. М., Иванов С. В., Горбатова М. А. Исследования типа «случай-контроль» в здравоохранении // Наука и Здравоохранение. 2015. № 4. С. 5-17.
4. Емельянова А. Н., Витковский Ю. А. Генетический полиморфизм IL-10 и CRP у больных с циррозом печени вирусной этиологии // Сибирский медицинский журнал (Иркутск). 2013. №4. С. 39-41.
5. Масабаева М. Р.; Аукенов Н. Е. и др. Молекулярно-генетические механизмы развития осложнений хронических вирусных гепатитов B и C (Обзор литературы) // Наука и здравоохранение. 2014. № 1. С. 11–14.
6. Сегизбаева А. К., Шаймерденов С. А., Рахметова В. С. Организация медицинской помощи больным с вирусными гепатитами в Гепатологическом центре Астаны // Клиническая медицина Казахстана. 2013. №1 (27). С.9-10.
7. Руднева Е. Хельсинская декларация этических принципов: версия 2008г. // Український медичний часопис. 2009. №. 1. С. 69.
8. Самоходская Л. М. и др. Прогностическое значение комбинации аллельных вариантов генов цитокинов и гемохроматоза у больных хроническим гепатитом С // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2007. Т. 17. №. 2. С. 50-56.
9. Шайзадина Ф. М. и др. Эпидемиологи-ческая ситуация вирусных гепатитов в небольшом городе центрального Казахстана // Международный журнал прикладных и фундаментальных исследований. 2013. №.8. С. 3.
10. Akdis C. A., Akdis M. Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs // J Clin Invest. 2014. Т. 124. №. 11. P. 4678-80.
11. Fu C. et al. β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10 // Proceedings of the National Academy of Sciences. 2015. №. 9. P. 2823-2828.
12. Gerger A. et al. Association of interleukin-10 gene variation with breast cancer prognosis // Breast cancer research and treatment. 2010. Т. 119. №.3. P. 701-705.
13. Hatzakis A. et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm–volume 2 // Journal of viral hepatitis. 2015. Т. 22. №. s1. P. 26-45.
14. Imran M., Manzoor S., Ashraf J., Khalid M., Tariq M., Khaliq H. M., & Azam S. Role of viral and host factors in interferon based therapy of hepatitis C virus infection // Virol J. 2013. Т. 10. Р. 299.
15. Jacobson I. M., Gordon S. C., Kowdley K. V., Yoshida E. M., Rodriguez-Torres M., Sulkowski M. S. et al.. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options // N Engl J Med. 2013. P. 77.
16. Langsenlehner U. et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk // Breast cancer research and treatment. 2005. Т. 90. №. 2. P. 113-115.
17. Locarnini S. et al. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs // Journal of hepatology. 2015. Т. 62. №. 1. P. 76-86.
18. Nelson D. R. et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders // Gastroenterology. 2000. Т. 118. №. 4. P. 655-660.
19. Ren H., Zhang T. T., Hu W. L. A-819 C/T polymorphism in the interleukin-10 promoter is associated with persistent HBV infection, but-1082 A/G and-592A/C polymorphisms are not: a meta-analysis // Archives of virology. 2015. Т. 160. №. 3. P. 747-756.
20. Sweeney L. et al. Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionals // BMC health services research. 2015. Т. 15. №. 1. P. 97.
21. Thompson K. et al. Interleukin‐10 expression and function in experimental murine liver inflammation and fibrosis // Hepatology. 1998. Т. 28. №. 6. P. 1597-1606.
22. Wang S., Huang D., Sun S., Ma W., & Zhen Q. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alpha // Virology journal. 2011. Т. 8. №. 28. Р. 422.
23. World Health Organization et al. The Third Hepatitis B Expert Resource Panel Consultation, 12-13 January 2015, Seoul, Republic of Korea: report. – Manila: WHO Regional Office for the Western Pacific, 2015.
24. Yee L. J. et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection // Hepatology. 2001. Т. 33. №. 3. P. 708-712.
25. Yuan J. M. et al. Genetic polymorphisms of epidermal growth factor in relation to risk of hepatocellular carcinoma: two case-control studies // BMC gastroenterology. 2013. №. 1. P. 32.
26. Zhao Q. et al. Epigenetic modifications in hepatic stellate cells contribute to liver fibrosis // The Tohoku journal of experimental medicine. 2013. Т. 229. №. 1. P. 35-43.
References:
1. Arsent'eva N. A., Semenov A. V., Totolyan A. A. Rol' polimorfizma genov tsitokinov pri virusnom gepatite C [Role polymorphism of genes cytokine at viral hepatitis C]. Infektsiya i immunitet [Infection and immunology]. 2012, 4, pp. 687-698.
2. Bodienkova G. M., Titova Zh. V. Rol' polimorfizma i ekspressii otdel'nykh genov tsitokinov v formirovanii patologii (Obzor) [The role of polymorphism and expression of separate genes cytokine in formation of pathology (Review)]. Uspekhi sovremennogo estestvoznaniya [Achievements of modern natural sciences]. 2015, 1, pp. 4.
3. Grzhibovskii A. M., Ivanov S. V., Gorbatova M. A. Issledovaniya tipa «sluchai-kontrol'» v zdravookhranenii ["Case-control" researches in health care]. Nauka i Zdravookhranenie [Science & Healthcare]. 2015, 4, pp. 5-17. [in Kazakhstan]
4. Emel'yanova A. N., Vitkovskii Yu. A. Geneticheskii polimorfizm IL-10 i CRP u bol'nykh s tsirrozom pecheni virusnoi etiologii [Genetic polymorphism of IL-10 and CRP at patients with cirrhosis of a virus etiology]. Sibirskii meditsinskii zhurnal (Irkutsk) [The Siberian medical journal (Irkutsk)]. 2013, 4, pp. 39-41.
5. Masabaeva M. R.; Aukenov N. E. et al. Molekulyarno-geneticheskie mekhanizmy razvitiya oslozhnenii khronicheskikh virusnykh gepatitov B i C (Obzor literatury) [Molecular genetic mechanisms of developing complications of chronic viral hepatitis B and C (Literature review)]. Nauka i zdravoohranenie [Science & Healthcare]. 2014, 1, рр. 11–14. [in Kazakhstan]
6. Segizbaeva A. K., Shaimerdenov S. A., Rakhmetova V. S. Organizatsiya meditsinskoi pomoshchi bol'nym s virusnymi gepatitami v Gepatologicheskom tsentre Astany [The organization of medical care by the patient with viral hepatitis in the Gepatology center of Astana]. Klinicheskaya meditsina Kazakhstana [Clinical medicine of Kazakhstan]. 2013, 1, pp.9-10.
7. Rudneva E. Khel'sinskaya deklaratsiya eticheskikh printsipov: versiya 2008 g [Helsinki declaration of ethical principles: version of 2008]. Ukraїns'kii medichnii chasopis [Ukrainian medical magazine]. 2009, 1, pp. 69.
8. Samokhodskaya L. M. et al. Prognosticheskoe znachenie kombinatsii allel'nykh variantov genov tsitokinov i gemokhromatoza u bol'nykh khronicheskim gepatitom C [Predictive value of a combination of allelic options of genes of cytokine and hemochromatosis at patients with chronic hepatitis C]. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii [The Russian journal of gastroenterology, hepatology and coloproctology]. 2007, 2, pp. 50-56.
9. Shaizadina F. M. et al. Epidemiologicheskaya situatsiya virusnykh gepatitov v nebol'shom gorode tsentral'nogo Kazakhstana [Epidemiological situation of viral hepatitis in the small city of the central Kazakhstan]. Mezhdunarodnyi zhurnal prikladnykh i fundamental'nykh issledovanii [International journal of applied and basic researches.]. 2013, 8, pp. 3.
10. Akdis C. A., Akdis M. Mechanisms of immune tolerance to allergens: role of IL-10 and Tregs. J Clin Invest. 2014, 11, pp. 4678-80.
11. Fu C. et al. β-Catenin in dendritic cells exerts opposite functions in cross-priming and maintenance of CD8+ T cells through regulation of IL-10. Proceedings of the National Academy of Sciences. 2015, 9, pp. 2823-2828.
12. Gerger A. et al. Association of interleukin-10 gene variation with breast cancer prognosis. Breast cancer research and treatment. 2010, 3, pp. 701-705.
13. Hatzakis A. et al. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm–volume 2. Journal of viral hepatitis. 2015, s1, pp. 26-45.
14. Imran M., Manzoor S., Ashraf J., Khalid M., Tariq M., Khaliq H. M., & Azam S. Role of viral and host factors in interferon based therapy of hepatitis C virus infection. Virol J. 2013, 10, pp. 299.
15. Jacobson I. M., Gordon S. C., Kowdley K.V., Yoshida E. M., Rodriguez-Torres M., Sulkowski M. S. et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013. pp. 77.
16. Langsenlehner U. et al. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast cancer research and treatment. 2005, 2, pp. 113-115.
17. Locarnini S. et al. Strategies to control hepatitis B: Public policy, epidemiology, vaccine and drugs. Journal of hepatology. 2015, 1, pp. 76-86.
18. Nelson D. R. et al. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders. Gastroenterology. 2000, 4, pp. 655-660.
19. Ren H., Zhang T. T., Hu W. L. A-819 C/T polymorphism in the interleukin-10 promoter is associated with persistent HBV infection, but-1082 A/G and-592A/C polymorphisms are not: a meta-analysis. Archives of virology. 2015, 3, pp. 747-756.
20. Sweeney L. et al. Informing the design of a national screening and treatment programme for chronic viral hepatitis in primary care: qualitative study of at-risk immigrant communities and healthcare professionals. BMC health services research. 2015, 1, pp. 97.
21. Thompson K. et al. Interleukin‐10 expression and function in experimental murine liver inflammation and fibrosis. Hepatology. 1998, 6, pp. 1597-1606.
22. Wang, S., Huang, D., Sun, S., Ma, W., & Zhen, Q. Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alpha. Virology journal. 2011, 28, pp. 422.
23. World Health Organization et al. The Third Hepatitis B Expert Resource Panel Consultation, 12-13 January 2015, Seoul, Republic of Korea: report. – Manila: WHO Regional Office for the Western Pacific, 2015.
24. Yee L. J. et al. Interleukin 10 polymorphisms as predictors of sustained response in antiviral therapy for chronic hepatitis C infection. Hepatology. 2001, 3, pp. 708-712.
25. Yuan J. M. et al. Genetic polymorphisms of epidermal growth factor in relation to risk of hepatocellular carcinoma: two case-control studies. BMC gastroenterology. 2013, 1, pp. 32.
26. Zhao Q. et al. Epigenetic modifications in hepatic stellate cells contribute to liver fibrosis. The Tohoku journal of experimental medicine. 2013, 1, pp. 35-43.
Number of Views: 327
Category of articles:
Original articles
Bibliography link
Massabayeva M. R., Aukenov N. E., Babenko D. B., Azizov I. S., Maukayeva S. B., Tokayeva A. Z., Khamitova M. O. Assessment of impact of gene polymorphism IL-10 on outcomes of chronic viral hepatitis in kazakh population: case-control study. Nauka i Zdravoohranenie [Science & Healthcare]. 2015, 6, pp. 67-76.Related publications:
ANALYSIS OF CLINICAL AND DEMOGRAPHIC INDICATORS OF PATIENTS WITH PARKINSON'S DISEASE IN THE SOUTHERN REGION OF KAZAKHSTAN
A COMPARATIVE STUDY OF DRUG POLICY REGARDING ORPHAN DISEASES IN THE USA, THE EUROPEAN UNION, AND THE REPUBLIC OF KAZAKHSTAN
MUTATIONS IN CARDIAC ION CHANNEL GENES IN KAZAKHSTANI PATIENTS WITH LONG QT SYNDROME
GENETIC FEATURES OF CONGENITAL DYSFUNCTION OF THE ADRENAL CORTEX CAUSED BY 21-HYDROXYLASE DEFICIENCY IN PERSONS OF KAZAKH NATIONALITY
NON-MOTOR SYMPTOMS IN PARKINSON'S DISEASE USING THE EXAMPLE OF AKTOBE PATIENTS